AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2004 NOV 3 - (NewsRx.com & NewsRx.net) -- Magistral Biotech (MBS) announced two new multi-center clinical studies that will study the effectiveness of Magistral's over-the-counter, cholesterol-lowering drug Libracol when taken concomitantly with Lipitor, Canada's biggest-selling statin, which is marketed by Pfizer.
Andre Aube, Magistral's president and CEO said, "we would not risk pairing our product with a drug of the caliber of Lipitor unless we were highly confident that we would obtain a superior efficacy rate than with the drug alone, while at the same time preventing side effects." This clinical study will compare the effects of the two products in combination therapy with results obtained by patients currently taking Lipitor alone, whose treatment has leveled off. According to Magistral's statement, previous studies have shown that Libracol can reduce cholesterol levels by approximately 40%.
Magistral said that one of these studies deals with Libracol as a single agent, and should demonstrate the effectiveness of Libracol with HEP-30 to ...